QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)

Biotech Stocks List

Compare biotech stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Learn more about trading biotech stocks.

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$224.23
-0.4%
$239.07
$220.44
$296.67
$119.81 B0.642.34 million shs2.23 million shs
Biogen Inc. stock logo
BIIB
Biogen
$305.45
-0.3%
$286.80
$188.54
$319.74
$44.21 B0.19981,132 shs616,593 shs
BioNTech SE stock logo
BNTX
BioNTech
$104.95
-0.2%
$120.51
$100.08
$188.99
$25.52 B0.21686,843 shs604,446 shs
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$78.21
-0.8%
$81.15
$57.17
$89.74
$97.56 B0.385.85 million shs5.05 million shs
Illumina, Inc. stock logo
ILMN
Illumina
$201.29
+1.9%
$217.05
$173.45
$258.07
$31.82 B1.181.27 million shs1.13 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$125.33
-0.2%
$143.39
$115.03
$217.25
$47.78 B1.73.55 million shs2.99 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$747.48
-0.3%
$788.45
$538.01
$837.55
$81.72 B0.23600,803 shs501,269 shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$339.46
-0.5%
$323.72
$243.17
$354.46
$87.43 B0.491.20 million shs1.14 million shs
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$195.45
+1.2%
$194.10
$165.75
$249.11
$36.27 B1.391.05 million shs1.24 million shs
Mettler-Toledo International Inc. stock logo
MTD
Mettler-Toledo International
$1,384.43
+1.1%
$1,481.76
$1,065.55
$1,615.97
$30.49 B1.1795,009 shs74,154 shs

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
-1.26%-3.88%-9.29%-3.93%-8.29%
Biogen Inc. stock logo
BIIB
Biogen
-0.44%-2.24%+4.81%+12.79%+50.94%
BioNTech SE stock logo
BNTX
BioNTech
-0.43%+2.49%-15.71%-25.63%-34.20%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
+0.63%+0.90%-5.76%-5.49%+24.74%
Illumina, Inc. stock logo
ILMN
Illumina
-2.20%-5.73%-14.13%-6.77%-18.81%
Moderna, Inc. stock logo
MRNA
Moderna
+0.37%-4.02%-12.78%-27.13%-11.74%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
+0.99%+0.01%-8.55%+1.81%+12.29%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
-1.14%-2.53%+4.11%+16.83%+30.31%
IQVIA Holdings Inc. stock logo
IQV
IQVIA
+0.96%+2.64%-4.72%-13.82%-6.60%
Mettler-Toledo International Inc. stock logo
MTD
Mettler-Toledo International
-0.27%-0.22%-14.21%-10.77%+10.74%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amgen Inc. stock logo
AMGN
Amgen
2.6709 of 5 stars
2.14.05.03.92.11.71.9
Biogen Inc. stock logo
BIIB
Biogen
2.2619 of 5 stars
2.43.00.03.72.52.51.9
BioNTech SE stock logo
BNTX
BioNTech
2.4233 of 5 stars
4.24.00.00.01.80.81.3
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
3.0957 of 5 stars
2.33.04.24.12.82.53.8
Illumina, Inc. stock logo
ILMN
Illumina
2.6433 of 5 stars
3.24.00.04.22.42.51.9
Moderna, Inc. stock logo
MRNA
Moderna
2.6877 of 5 stars
4.21.00.04.62.93.31.3
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.6606 of 5 stars
3.44.00.03.72.52.51.9
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
2.2542 of 5 stars
1.34.00.03.33.72.52.5
IQVIA Holdings Inc. stock logo
IQV
IQVIA
2.8977 of 5 stars
3.55.00.04.62.41.72.5
Mettler-Toledo International Inc. stock logo
MTD
Mettler-Toledo International
1.7733 of 5 stars
1.12.00.03.31.52.52.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amgen Inc. stock logo
AMGN
Amgen
2.15
Hold$250.9411.91% Upside
Biogen Inc. stock logo
BIIB
Biogen
2.81
Moderate Buy$328.387.51% Upside
BioNTech SE stock logo
BNTX
BioNTech
2.42
Hold$173.0064.84% Upside
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.53
Moderate Buy$91.0016.35% Upside
Illumina, Inc. stock logo
ILMN
Illumina
2.38
Hold$253.7026.04% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.36
Hold$179.1342.93% Upside
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.75
Moderate Buy$850.2113.74% Upside
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
2.67
Moderate Buy$352.593.87% Upside
IQVIA Holdings Inc. stock logo
IQV
IQVIA
2.92
Moderate Buy$253.2529.57% Upside
Mettler-Toledo International Inc. stock logo
MTD
Mettler-Toledo International
2.29
Hold$1,469.506.14% Upside

Current Analyst Ratings

Latest Biotech Stocks Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/18/2023
BioNTech SE stock logo
BNTX
BioNTech
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$135.00 ➝ $120.00
5/17/2023
BioNTech SE stock logo
BNTX
BioNTech
Redburn Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$165.00 ➝ $170.00
5/16/2023
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$90.00 ➝ $100.00
5/11/2023
Biogen Inc. stock logo
BIIB
Biogen
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price Target$320.00 ➝ $350.00
5/8/2023
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$960.00 ➝ $935.00
5/8/2023
Mettler-Toledo International Inc. stock logo
MTD
Mettler-Toledo International
51job
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMaintains
5/8/2023
Mettler-Toledo International Inc. stock logo
MTD
Mettler-Toledo International
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$1,675.00 ➝ $1,660.00
5/8/2023
Mettler-Toledo International Inc. stock logo
MTD
Mettler-Toledo International
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$1,700.00 ➝ $1,650.00
5/8/2023
Mettler-Toledo International Inc. stock logo
MTD
Mettler-Toledo International
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$1,513.00 ➝ $1,454.00
5/7/2023
Mettler-Toledo International Inc. stock logo
MTD
Mettler-Toledo International
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$1,650.00 ➝ $1,525.00
5/5/2023
Moderna, Inc. stock logo
MRNA
Moderna
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$185.00 ➝ $153.00
(Data available from 5/18/2020 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amgen Inc. stock logo
AMGN
Amgen
$26.32B4.55$23.96 per share9.36$10.01 per share22.40
Biogen Inc. stock logo
BIIB
Biogen
$10.17B4.35$21.36 per share14.30$95.25 per share3.21
BioNTech SE stock logo
BNTX
BioNTech
$18.24B1.40$41.32 per share2.54$89.44 per share1.17
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$27.28B3.58$8.97 per share8.72$16.79 per share4.66
Illumina, Inc. stock logo
ILMN
Illumina
$4.58B6.94$4.63 per share43.51$42.33 per share4.76
Moderna, Inc. stock logo
MRNA
Moderna
$19.26B2.48$22.79 per share5.50$49.48 per share2.53
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$12.37B6.61$44.84 per share16.67$214.91 per share3.48
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$8.93B9.79$13.76 per share24.67$56.04 per share6.06
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$14.41B2.52$16.11 per share12.13$31.97 per share6.11
Mettler-Toledo International Inc. stock logo
MTD
Mettler-Toledo International
$3.95B7.72$46.24 per share29.94($1.11) per share-1,247.23

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amgen Inc. stock logo
AMGN
Amgen
$6.55B$14.7115.2411.611.8030.23%248.47%13.54%8/3/2023 (Estimated)
Biogen Inc. stock logo
BIIB
Biogen
$3.05B$21.5414.1818.752.5530.99%19.60%10.25%7/19/2023 (Estimated)
BioNTech SE stock logo
BNTX
BioNTech
$9.94B$26.014.0339.75N/A51.03%32.52%27.56%8/14/2023 (Estimated)
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$4.59B$4.4317.6510.770.9020.65%39.35%13.11%8/1/2023 (Estimated)
Illumina, Inc. stock logo
ILMN
Illumina
-$4.40B-$28.53N/A60.456.49-100.92%2.26%1.36%8/10/2023 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
$8.36B$11.5710.83N/AN/A31.77%25.87%18.75%8/2/2023 (Estimated)
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$4.34B$36.8020.3120.512.3733.81%20.41%15.79%8/2/2023 (Estimated)
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$3.32B$12.5627.0324.373.2435.40%25.06%19.25%8/3/2023 (Estimated)
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$1.09B$5.5635.1518.541.927.28%30.95%6.95%7/20/2023 (Estimated)
Mettler-Toledo International Inc. stock logo
MTD
Mettler-Toledo International
$872.50M$39.3835.1628.292.3422.45%-4,833.51%26.87%7/27/2023 (Estimated)

Latest Biotech Stocks Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/20233/31/2023
BioNTech SE stock logo
BNTX
BioNTech
$0.18$2.05+$1.87$2.20$1.09 billion$1.28 billion    
5/4/2023Q1 2023
Moderna, Inc. stock logo
MRNA
Moderna
-$1.77$0.19+$1.96$0.19$1.17 billion$1.86 billion    
5/4/2023Q1 23
Mettler-Toledo International Inc. stock logo
MTD
Mettler-Toledo International
$8.61$8.69+$0.08$8.91$921.19 million$928.70 million    
5/1/2023Q1 23
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$2.51$3.05+$0.54$2.65$2.34 billion$2.37 billion    
4/27/2023Q1 2023
Amgen Inc. stock logo
AMGN
Amgen
$3.84$3.98+$0.14$2.68$6.18 billion$6.11 billion    
4/27/2023Q1 2023
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$1.63$1.37-$0.26$1.94$6.33 billion$6.35 billion    
4/25/2023Q1 2023
Biogen Inc. stock logo
BIIB
Biogen
$3.25$3.40+$0.15$4.13$2.34 billion$2.46 billion      
4/25/2023Q1 2023
Illumina, Inc. stock logo
ILMN
Illumina
$0.02$0.08+$0.06$0.14$1.07 billion$1.09 billion    
3/27/202312/31/2022
BioNTech SE stock logo
BNTX
BioNTech
$8.04$9.26+$1.22$9.46$3.87 billion$4.28 billion    
2/23/2023Q4 2022
Moderna, Inc. stock logo
MRNA
Moderna
$4.66$3.61-$1.05$3.61$5.02 billion$5.08 billion      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amgen Inc. stock logo
AMGN
Amgen
$8.523.80%+10.14%57.92%11 Years
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
BioNTech SE stock logo
BNTX
BioNTech
N/AN/AN/AN/AN/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.003.84%+5.03%67.72%8 Years
Illumina, Inc. stock logo
ILMN
Illumina
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
N/AN/AN/AN/AN/A
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/AN/AN/AN/AN/A
IQVIA Holdings Inc. stock logo
IQV
IQVIA
N/AN/AN/AN/AN/A
Mettler-Toledo International Inc. stock logo
MTD
Mettler-Toledo International
N/AN/AN/AN/AN/A

Latest Biotech Stocks Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/25/2023
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Quarterly$0.753.65%6/14/20236/15/20236/29/2023
3/7/2023
Amgen Inc. stock logo
AMGN
Amgen
quarterly$2.133.73%5/17/20235/18/20236/8/2023
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amgen Inc. stock logo
AMGN
Amgen
11.36
3.14
2.79
Biogen Inc. stock logo
BIIB
Biogen
0.46
3.24
2.81
BioNTech SE stock logo
BNTX
BioNTech
0.01
12.95
12.68
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1.10
1.28
1.13
Illumina, Inc. stock logo
ILMN
Illumina
0.22
1.42
1.16
Moderna, Inc. stock logo
MRNA
Moderna
0.04
3.46
3.26
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.11
5.45
4.67
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.03
4.28
4.11
IQVIA Holdings Inc. stock logo
IQV
IQVIA
1.99
0.80
0.80
Mettler-Toledo International Inc. stock logo
MTD
Mettler-Toledo International
76.98
1.28
0.86

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Amgen Inc. stock logo
AMGN
Amgen
25,200534.33 million531.28 millionOptionable
Biogen Inc. stock logo
BIIB
Biogen
8,725144.74 million143.80 millionOptionable
BioNTech SE stock logo
BNTX
BioNTech
4,530243.21 million196.52 millionNot Optionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
17,0001.25 billion1.24 billionOptionable
Illumina, Inc. stock logo
ILMN
Illumina
10,260158.10 million157.89 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
3,900381.21 million321.36 millionOptionable
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
11,851109.33 million99.67 millionOptionable
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
4,800257.55 million256.78 millionOptionable
IQVIA Holdings Inc. stock logo
IQV
IQVIA
86,000185.55 million182.77 millionOptionable
Mettler-Toledo International Inc. stock logo
MTD
Mettler-Toledo International
18,00022.02 million21.49 millionOptionable

Biotech Stocks Headlines

SourceHeadline
Mettler-Toledo International (MTD) Rose on Strong Financial ResultsMettler-Toledo International (MTD) Rose on Strong Financial Results
finance.yahoo.com - May 18 at 8:32 AM
Mettler-Toledo International (NYSE:MTD) Coverage Initiated at StockNews.comMettler-Toledo International (NYSE:MTD) Coverage Initiated at StockNews.com
americanbankingnews.com - May 18 at 7:14 AM
Mettler-Toledo International Inc. (NYSE:MTD) CFO Shawn Vadala Sells 880 SharesMettler-Toledo International Inc. (NYSE:MTD) CFO Shawn Vadala Sells 880 Shares
americanbankingnews.com - May 17 at 6:24 AM
Mettler-Toledo International Inc. (NYSE: MTD) is a Leading Gainer in Friday Morning TradingMettler-Toledo International Inc. (NYSE: MTD) is a Leading Gainer in Friday Morning Trading
markets.buffalonews.com - May 12 at 3:22 PM
Cowen AND Company LLC Decreases Stock Holdings in Mettler-Toledo International Inc. (NYSE:MTD)Cowen AND Company LLC Decreases Stock Holdings in Mettler-Toledo International Inc. (NYSE:MTD)
marketbeat.com - May 12 at 8:36 AM
Wells Fargo & Company Trims Mettler-Toledo International (NYSE:MTD) Target Price to $1,660.00Wells Fargo & Company Trims Mettler-Toledo International (NYSE:MTD) Target Price to $1,660.00
americanbankingnews.com - May 11 at 5:16 AM
Mettler-Toledo International (NYSE:MTD) PT Lowered to $1,525.00 at Bank of AmericaMettler-Toledo International (NYSE:MTD) PT Lowered to $1,525.00 at Bank of America
americanbankingnews.com - May 10 at 3:42 AM
Mettler-Toledo Internationals (MTD) Maintains Rating Reaffirmed at 51jobMettler-Toledo International's (MTD) Maintains Rating Reaffirmed at 51job
americanbankingnews.com - May 9 at 6:36 AM
Mettler-Toledo International (NYSE:MTD) Given New $1,454.00 Price Target at Robert W. BairdMettler-Toledo International (NYSE:MTD) Given New $1,454.00 Price Target at Robert W. Baird
americanbankingnews.com - May 9 at 5:55 AM
Bank of America Lowers Mettler-Toledo International (NYSE:MTD) Price Target to $1,525.00Bank of America Lowers Mettler-Toledo International (NYSE:MTD) Price Target to $1,525.00
americanbankingnews.com - May 9 at 2:00 AM
B of A Securities Maintains Mettler Toledo International (MTD) Neutral RecommendationB of A Securities Maintains Mettler Toledo International (MTD) Neutral Recommendation
msn.com - May 8 at 5:32 PM
Baird Maintains Mettler Toledo International (MTD) Neutral RecommendationBaird Maintains Mettler Toledo International (MTD) Neutral Recommendation
msn.com - May 8 at 5:32 PM
Mettler-Toledo International Inc. stock falls Monday, underperforms marketMettler-Toledo International Inc. stock falls Monday, underperforms market
marketwatch.com - May 8 at 5:32 PM
5 Analysts Have This to Say About Mettler-Toledo Intl5 Analysts Have This to Say About Mettler-Toledo Intl
markets.businessinsider.com - May 8 at 12:32 PM
Mettler-Toledo International (NYSE:MTD) Price Target Cut to $1,650.00Mettler-Toledo International (NYSE:MTD) Price Target Cut to $1,650.00
americanbankingnews.com - May 8 at 9:00 AM
Mettler-Toledo International Inc. stock underperforms Friday when compared to competitorsMettler-Toledo International Inc. stock underperforms Friday when compared to competitors
marketwatch.com - May 5 at 8:25 PM
Mettler-Toledo International shares are trading lower after the company issued Q2 adjusted EPS guidance below estimates.Mettler-Toledo International shares are trading lower after the company issued Q2 adjusted EPS guidance below estimates.
benzinga.com - May 5 at 3:13 PM
Mettler-Toledo International Inc. 2023 Q1 - Results - Earnings Call PresentationMettler-Toledo International Inc. 2023 Q1 - Results - Earnings Call Presentation
seekingalpha.com - May 5 at 11:44 AM
Russell Investments Group Ltd. Sells 79 Shares of Mettler-Toledo International Inc. (NYSE:MTD)Russell Investments Group Ltd. Sells 79 Shares of Mettler-Toledo International Inc. (NYSE:MTD)
marketbeat.com - May 5 at 9:28 AM
Mettler-Toledo Intl: Q1 Earnings InsightsMettler-Toledo Intl: Q1 Earnings Insights
msn.com - May 4 at 8:12 PM
Mettler-Toledo International Inc. Reports First Quarter 2023 ResultsMettler-Toledo International Inc. Reports First Quarter 2023 Results
finance.yahoo.com - May 4 at 8:12 PM
Analysts Set Mettler-Toledo International Inc. (NYSE:MTD) Target Price at $1,450.71Analysts Set Mettler-Toledo International Inc. (NYSE:MTD) Target Price at $1,450.71
americanbankingnews.com - May 4 at 1:18 AM
Mettler-Toledo International Inc. stock falls Wednesday, still outperforms marketMettler-Toledo International Inc. stock falls Wednesday, still outperforms market
marketwatch.com - May 3 at 8:18 PM
What to Note Ahead of Mettler-Toledos (MTD) Q1 Earnings?What to Note Ahead of Mettler-Toledo's (MTD) Q1 Earnings?
finance.yahoo.com - May 3 at 3:18 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Amgen logo

Amgen

NASDAQ:AMGN
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
Biogen logo

Biogen

NASDAQ:BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
BioNTech logo

BioNTech

NASDAQ:BNTX
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; Regeneron Pharmaceuticals, Inc. and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Gilead Sciences logo

Gilead Sciences

NASDAQ:GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Illumina logo

Illumina

NASDAQ:ILMN
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.
Moderna logo

Moderna

NASDAQ:MRNA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Regeneron Pharmaceuticals logo

Regeneron Pharmaceuticals

NASDAQ:REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Vertex Pharmaceuticals logo

Vertex Pharmaceuticals

NASDAQ:VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
IQVIA logo

IQVIA

NYSE:IQV
IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the broader healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.
Mettler-Toledo International logo

Mettler-Toledo International

NYSE:MTD
Mettler-Toledo International, Inc. engages in the provision of precision instruments and services. The firm manufactures weighing instruments for use in laboratory, industrial, packaging, logistics, and food retailing applications. It also manufactures several related analytical instruments and provides automated chemistry solutions used in drug and chemical compound discovery and development, metal detection and other end-of-line inspection systems used in production and packaging and provides solutions for use in certain process analytics applications. Its operations are conducted by the following segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The U.S. Operations segment represents certain of the company's marketing and producing organizations located in the United States. The Swiss Operations segment includes marketing and producing organizations located in Switzerland, as well as extensive R&D operations that are responsible for the development, production, and marketing of precision instruments, including weighing, analytical, and measurement technologies for use in a variety of industrial and laboratory applications. T

Key Points

  • Biotech companies are among the market's riskiest investments, but that's exactly why they have potential for high returns.
  • Investors interested in biotech can mitigate their risk in several ways, including focusing on stocks traded on major exchanges or purchasing a basket of biotech stocks through an exchange-traded fund.
  • Because successful clinical trials and regulatory approval are not guaranteed, investors can see sudden, sharp drops in their biotech stocks.
  • A successful trial or FDA approval can result in big upside trade, as can an acquisition from a bigger pharmaceutical company. 

Have you been wondering how to invest in biotech stocks? You may have watched biotechs rallying fast and posting significant gains and felt you missed out. You may have also seen biotechs and biopharma stocks reward shareholders when acquired.

There are a few factors to consider when considering investing in biotech. In this article, we'll look at whether biotech stocks are a good fit for your portfolio and also some possible pitfalls to avoid. 

What Are Biotech Stocks?

Biotechs are established to develop specific medicines or therapeutic treatments. Often, they focus on a single product. 

When looking for the best biotech stocks to buy, be aware that many companies with promising technologies have market capitalizations of less than $2 billion, often well under. Some are also categorized as penny stocks, priced below $5 a share.

These biotech startups frequently have no earnings and very little revenue, as their operations are funded by venture capital

Many small biotechs generate a small amount of revenue by providing research services to large pharmaceuticals to supplement the venture capital, but their primary line of business is different. 

Biotechs are generally considered a risky category of investment. There is a great deal of potential in a company with a product successfully brought to market, but there is also the risk of disappointment.

how to invest in biotech stocks

Overview of the Biotechnology Industry

The biotechnology industry mainly focuses on research and development rather than building large manufacturing and distributing operations. 

The industry is risky, relying on a hit product brought to market. It's similar to the movie business, where a studio may invest millions into producing a motion picture, only to find that it flops when released. 

Similarly, biotech companies may go through years of research and development, only to learn that the treatment doesn't deliver the expected and hoped-for results in clinical trials. There's no guarantee that years of hard work and capital investment will pay off. But when it does, the treatment could eventually become a "blockbuster," a term it shares in common with Hollywood. 

To identify the top biotech stocks, remember that biotechs have similarities with pharmaceuticals but differ in some key ways. Pharmaceuticals bring existing, FDA-approved products to market. They have manufacturing and marketing chops, as you can see by the slew of drug commercials on TV. When you've been in a doctor's waiting room, you may have seen pharmaceutical sales reps arrive for a meeting to pitch their wares.

The biggest pharmaceutical companies, including Johnson & Johnson (NYSE: JNJ), Pfizer Inc. (NYSE: PFE), Roche Holding AG (OTCMKTS: RHHBY), AbbVie Inc. (NYSE: ABBV), Novartis AG (NYSE: NVS) and Merck & Co. Inc. (NYSE: MRK), typically acquire or license new treatments once already developed. They aren't taking the risk of research and development, which may not result in a marketable product. 

If you're interested in learning more about the differences and similarities between biotechs and pharmaceutical companies, you can do more research using MarketBeat's pharmaceutical stocks list

How to Buy Biotech Stocks

Investing in biotech stocks exposes you to a rapidly growing slice of the healthcare industry. For a broader look at the potential in all healthcare sectors, including biotech, you can use this list of healthcare stocks on MarketBeat.

To invest in biotech specifically, you could use a broad basket of stocks in an exchange-traded fund to capture industry-wide returns. 

Biotechs can, at times, outperform the broader stock market. For example, the iShares Biotechnology ETF (NYSEARCA: IBB) outperformed the S&P 500 on a 5-year, 10-year, and 15-year basis. That's not surprising, given the inherent volatility of biotech stocks and the potential for market-beating gains once a company has good news about clinical trials or a treatment gets the nod from regulators. 

Here are some steps you can take to get started with biotech investments. 

Step 1: Do your research.

Much like biotechs are research-focused, biotech investors must also understand what they buy. This may include studying the company's website, where you can read news, press releases and earnings reports, which contain updates on progress on clinical trials and regulatory approvals, even before a company is profitable. 

You can also review a list of healthcare stocks on MarketBeat to learn how a company you're interested in fits within the healthcare industry. 

Step 2: Understand the risks.

We can't emphasize this step enough. Biotech stocks are among the market's most volatile. For example, poor results from a clinical trial can send a stock sharply lower, with no previous warning. A delay in FDA approval can also mean a fast price drop. 

Prepare yourself for the possibility of significant losses. Biotech investors must be able to stomach a rollercoaster ride of volatility because it happens often. 

Step 3: Invest in stocks listed on major exchanges.

Plenty of biotechs are small companies characterized as penny stocks, which trade under $5 a share. In addition, biotechs are inherently riskier than some other categories. One way of potentially mitigating risk is by investing only in biotechs listed on the NYSE or Nasdaq exchanges. Those stocks are subject to greater regulatory scrutiny than stocks listed over the counter. 

Step 4: Focus on companies close to bringing a drug to market.

Another way to reduce risk is by focusing on biotechs that have already shown success in clinical trials and have applied for FDA approval. That can eliminate some of the sharp downsides in a company's stock that's only in the early stages of development and which may see clinical failures that wipe out shareholder value in a heartbeat. 

Step 5: Purchase stocks based on your investment objectives.

Because biotechs are inherently riskier than, say, utilities, it's important to know the role biotech plays. 

Understand that your biotech investment is more likely than bigger, more established companies to show big price swings that could bring down portfolio value. 

If you want exposure to the sector without such a wild ride, an ETF could smooth your biotech investment and reduce your risk. In addition to the iShares Biotechnology ETF, biotech ETFs include the SPDR S&P Biotech ETF (NYSEARCA: XBI) and the VanEck Biotech ETF (NASDAQ: BBH)

Step 6: Monitor your investment.

After you purchase a biotech stock or ETF, monitor your investment regularly. Keep an eye on the company's financial reports, news about clinical trials or partnerships, and broad-market trends that may affect the stock's performance. For example, 2022 was a bad year for biotech dealmaking, as less venture capital was entering the industry. That can slow research and development. 

Steps and Phases for Developing New Drugs 

Before a biotech firm can bring a product to market, it must go through several steps and phases. Investors should understand these processes, as they can greatly affect company operations and the stock's price.  

  • Research and development: This generally involves identifying a target disease or condition, developing processes for testing potential drug candidates, and optimizing the drug's formulation, safety, and efficacy for patient use.
  • Preclinical testing: A biotech can't simply begin testing its formulation on humans. This stage may involve pharmacology, toxicology studies and other types of laboratory testing. Some industry experts say animal testing will become less prevalent as new technologies such as organ-on-a-chip (OOC) and advanced computer modeling offer insights into how humans respond. 
  • Clinical trials: Clinical trials test the safety and efficacy of the drug in humans. These are conducted in three phases, using more participants and more rigorous testing protocols each time. Clinical trial news often moves a biotech's stock price sharply in either direction.
  • Regulatory approval: Once a drug has successfully completed clinical trials, the developer must get regulatory approval from agencies such as the FDA before it can be commercialized. This process involves submitting a new drug or marketing authorization application with all the clinical and preclinical data the company has generated.
  • Manufacturing: Once the drug has regulatory approval, the company must begin manufacturing the manufacturing process. Many small, new biotechs are not equipped for manufacturing in-house, so they often hire a contract manufacturer. Another avenue is to license the technology to a large pharmaceutical firm with large-scale manufacturing capabilities. Often because of the contributions of biotechs to their portfolios, it's possible to invest in pharmacy stocks for big gains
  • Marketing: The final step is marketing and selling the product to healthcare providers, insurance companies, and patients. This may involve working with distributors and developing marketing campaigns to raise awareness of the drug's benefits.

Pros and Cons of Investing in Biotech

Investment in any sector or asset class has pros and cons, which is true for biotech. Because the sector is notoriously volatile, you should understand the pros and cons. 

Pros 

Biotech investing can be very lucrative for some key reasons: 

  • Price appreciation: The old concept of buy low, sell high is very clear with biotech stocks. If a company has successful clinical trial data or gets regulatory approval, its stock price could rocket significantly higher.
  • Innovation: Biotech companies are at the cutting edge of medical innovation. The market rewards companies with new technologies that bring obvious changes to people's lives, including treating diseases and chronic health conditions.  
  • Growth potential: Biotech companies can grow fast once a product is successfully brought to market. In addition, investors are often rewarded when a biotech is acquired by a larger pharmaceutical, a very common occurrence. 
  • Diversification: Investing in biotech companies can diversify an investment portfolio, as these companies are not not necessarily highly correlated to the broader market, simply due to their business models and research and development cycles. 

Cons 

The potential negatives of biotech investing include the following: 

  • High risk: Perhaps no other sector has so much inherent downside risk. Many products that these companies develop never make it out of clinical trials or never receive FDA approval. This means investors can see the stock price decline to nearly nothing. 
  • Lengthy development timelines: Biotech companies generally have long development cycles. This can translate to significant costs and delays in bringing products to market. Investors must be patient if they want the reward at the end of the process - if that reward comes at all. 
  • Clinical and regulatory uncertainty: Successful clinical trials and regulatory approvals are required before a biotech can bring a product to market. Both these processes can be lengthy and riddled with uncertainty. There's no guarantee of success. 
  • Limited access to capital: In shaky market conditions, such as 2022, investors, including venture capitalists and those on the public markets, may be hesitant to put more money into unproven biotech. This may result in a slower research and development process. 

Future of Biotech Stocks

As with infotech, the biotech industry should solve problems and improve conditions. Those are exactly the types of companies that the market rewards, as they can potentially increase revenue quickly. 

Possible growth areas of the biotech industry include: 

  • Gene therapy: Gene therapy can potentially upend the treatment of many genetic disorders, such as cystic fibrosis and sickle cell anemia. The FDA has already approved many gene therapies, and more are developing.
  • Immunotherapy: Industry analysts see a lot of promise in Immunotherapy for treating cancer by channeling the body's immune system to attack cancer cells. Here again, the FDA has already OK'd some therapies, and more are expected.
  • Artificial intelligence: Artificial intelligence is permeating nearly every industry at this point. In biotech, it's used to speed up and streamline drug discovery, clinical trial design, and patient monitoring. This could help rapidly accelerate the development of new drugs.

High Risk Can Result in High Reward 

In the stock market, risk and return are related. That investment premise is abundantly clear regarding biotech: Higher exposure to certain risk factors can result in a higher expected return, but that's not guaranteed. 

Biotech is an exciting and promising area, and investors with some patience, the stomach for volatility, and a high risk tolerance can potentially benefit.  

FAQs 

Here are a few of the most commonly asked questions about biotech investing.

Should you invest in biotech stocks?

Biotechs offer exposure to an industry with high potential for big price gains, but that also comes with higher-than-average downside risk. If clinical trials are disappointing, or if a new product fails to get FDA approval, your investment will almost certainly plummet in value. Conversely, successfully bringing a product to market can mean big rewards for investors, as can an acquisition by a larger company.

How can I invest in biotech with little money? 

If you have little money to invest, one way to minimize your risk is by purchasing a basket of biotechs using an ETF. This can often be a sound approach, as you aren't simply betting your entire investment on one biotech, which is an extremely risky prospect. An ETF spreads the risk among many biotechs, meaning you'll participate in the gains of more than one company. You'll also participate in losses of multiple companies, but an ETF will generally smooth your return and reduce volatility. 

Is biotech a safe investment?

No equity investment can be called safe. 

Young, small companies with unproven technologies populate the biotech industry. It can take years to bring a product to market. A company's clinical trials may fail. The product may never get regulatory approval. For those reasons, investing in biotech can never be considered safe, although there is potential for a high return. But that comes with a great deal of risk. 

My Account -